FindTrial
Sign In

Regulation of DNA methylation modification of Mesenchymal Stem Cells by Kidney-marrow Simultaneous Therapy in the treatment of osteoarthritis

Regulation of DNA methylation modification of Mesenchymal Stem Cells by Kidney-marrow Simultaneous Therapy in the treatment of osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032100
Enrollment
Unknown
Registered
2020-04-20
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

control:N/A
Experimental group:Bushen Yisui Formula

Sponsors

First affiliated hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Western medicine diagnosis: in 2018, the Chinese society of bone sciences revised the KOA clinical diagnostic criteria; 2. The average age of KOA patients was between 55 and 75 years old and required knee replacement.

Exclusion criteria

Exclusion criteria: 1. With other diseases affecting bone metabolism; 2. With rheumatoid diseases, such as systemic diseases, spondylitis or rheumatoid arthritis; 3. With a history of severe joints.

Design outcomes

Primary

MeasureTime frame
Dnmt3b expression;VAS score;WOMAC score;Imaging;—

Countries

China

Contacts

Public ContactPeijian Tong

First affiliated hospital of Zhejiang Chinese Medical University

tongpeijian@163.com+86 571 86613684

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026